Nonapnea Sleep Disorders in Patients Younger than 65 Years Are Significantly Associated with CKD: A Nationwide Population-Based Study

Hugo You-Hsien Lin1,2,3, Chi-Chih Hung1, Yu-Han Chang2, Ming-Yen Lin1, Ming-Yu Yang4, Shih-Shin Liang5, Wangta Liu5, Hung-Chun Chen1,6, Shang-Jyh Hwang1,3,6,7*

1 Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 2 Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, 3 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 4 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan, 5 Department of Biotechnology, College of Life Science, Kaohsiung Medical University, Kaohsiung, Taiwan, 6 Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 7 Institute of Population Sciences, National Health Research Institutes, Miaoli, Taiwan

* sjhwang@kmu.edu.tw

Abstract

Background
Nonapnea sleep disorders (NASD) and sleep-related problems are associated with poor health outcomes. However, the association between NASD and the development and prognosis of chronic kidney disease (CKD) has not been investigated thoroughly. We explored the association between CKD and NASD in Taiwan.

Methods
We conducted a population-based study using the Taiwan National Health Insurance database with 1,000,000 representative data for the period from January 1, 2000 to December 31, 2009. We investigated the incidence and risk of CKD in 7,006 newly diagnosed NASD cases compared with 21,018 people without NASD matched according to age, sex, index year, urbanization, region, and monthly income at a 1:3 ratio.

Results
The subsequent risk of CKD was 1.48-fold higher in the NASD cohort than in the control cohort (95% confidence interval [CI] = 1.26–1.73, p < 0.001). Men, older age, type 2 diabetes mellitus, and gout were significant factors associated with the increased risk of CKD (p < 0.001). Among different types of NASDs, patients with insomnia had a 52% increased risk of developing CKD (95% CI = 1.23–1.84; P < 0.01), whereas patients with sleep disturbance had a 49% increased risk of subsequent CKD (95% CI = 1.19–1.87; P < 0.001). Younger
women (aged < 65 years) were at a high risk of CKD with NASD (adjusted hazard ratio, [HR] = 1.81; 95% CI = 1.35–2.40, p< 0.001).

Conclusions

In this nationwide population-based cohort study, patients with NASD, particularly men of all ages and women aged younger than 65 years, were at high risk of CKD.

Introduction

The prevalence and incidence of chronic kidney disease (CKD) have increased over the past decade and this trend seems likely to continue. Thus, CKD is a growing public health problem worldwide [1,2]. Evaluating the risk factors for CKD is crucial because of the high all-cause mortality and cardiovascular disease associated with the disease [3]. Although CKD is mainly caused by hypertension and type 2 diabetes mellitus (DM)[4], the factors responsible for its development or progression have yet to be investigated. Hyperuricemia, dyslipidemia, obesity, and inflammation are other risk factors for CKD but are only partially responsible for the individual differences [5–8].

Sleep disorders are common conditions characterized by difficulty in initiating or maintaining sleep, accompanied by symptoms such as irritability or fatigue during wakefulness. The prevalence of nonapnea sleep disorders (NASD) in the general population is approximately 20%, of which approximately 50% are chronic cases that mostly remain undiagnosed [9]. The prevalence of sleep disorders and sleep-related problems (leg symptoms and nocturia) are higher in patients with CKD compared with patients without CKD [10]. Among sleep disorders, such as obstructive sleep apnea (OSA), are risk factors for cardiovascular disease (CVD), hypertension, stroke, CKD, and mortality [11,12]. The underlying pathogenesis of OSA comprises intermittent hypoxia, activated sympathetic nerve activity, systemic inflammation, and oxidative stress [13–15].

We evaluated the association of NASD with the risk of CKD in Taiwan, and the study data were obtained from Taiwan’s National Health Insurance Research Database (NHIRD).

Methods

Study Population

The National Health Insurance (NHI) program in Taiwan is a nationwide, compulsory, and comprehensive insurance system initiated in 1995 and established by the Bureau of National Health Insurance of the Department of Health. The NHI provides health care to 99% of the 23.74 million residents of Taiwan and is contracted with 97% of Taiwanese hospitals and clinics[16]. The NHIRD, one of the largest databases worldwide, is released for research and contains the claims data on one million people systematically selected from all the insurants. The NHIRD includes encrypted patient identification numbers, medical facility registries, details of ambulatory care, inpatient orders, dental services, prescribed drugs, and physicians providing services. The disorders diagnosed are coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).

This cohort study was approved by the Institutional Review Board of Kaohsiung Medical University (KMUH-IRB-EXEMPT-20140059).

Study Participants. We conducted a retrospective cohort study. Patients with sleep disorders, including nonorganic sleep disorders and sleep disturbances (ICD-9-CM codes 307.4x, 307.5x), were eligible for inclusion. The primary outcome was the occurrence of CKD, defined as a diagnosis of CKD according to ICD-9-CM codes 585.5x, 585.0x, or 585.2x.
newly diagnosed by physicians and who used benzodiazepine (BZD) before bedtime for at least 3 months between January 1, 2000 and December 31, 2010 according to the NHIRD records comprised the NASD cohort. The date of first NASD diagnosis was considered the index date. We excluded patients aged younger than 18 years, having sleep apnea syndrome (ICD-9-CM codes 780.51, 780.53, 780.57 and 327.23), and history of CKD (ICD-9-CM code 585) before the index date. NASD were classified into insomnia (ICD-9-CM code 780.52), sleep disturbance (ICD-9-CM code 780.5), unspecified sleep disturbance (ICD-9-CM code 780.50), unspecified hypersomnia (ICD-9-CM code 780.54), unspecified disruptions of 24-h sleep–wake cycle (ICD-9-CM code 780.55), dysfunctions associated with sleep stages or arousal from sleep (ICD-9-CM code 780.56), unspecified sleep-related movement disorder (ICD-9-CM code 780.58), other sleep disturbance (ICD-9-CM code 780.59), specific sleep disorders of nonorganic origin (ICD-9-CM code 307.4), restless legs syndrome (ICD-9-CM code 333.94), cataplexy and narcolepsy (ICD-9-CM code 347), and circadian rhythm sleep disorder (ICD-9-CM code 327.3x) [17]. The control cohort comprised randomly selected patients without a history of sleep disorders, and CKD, who were frequency matched according to sex, age, index year, urbanization, region, and monthly income. A matching procedure was applied to enhance the comparison between the NASD and control cohorts. The index year was defined as the year of NASD diagnosis for the NASD cohort, whereas it was the year of an outpatient visit for the control cohort. Age was calculated from the date of birth to the date of NASD diagnosis for the NASD cohort and from the date of birth to the date of the outpatient visit for the control cohort. The participants in the control cohort were matched with the NASD cohort at a 3:1 ratio. The follow-up period started from the date of entering the study cohort to the date of CKD event, censoring, or December 31, 2010 (Fig 1).

**Outcome Measures.** In Taiwan, patients with end-stage renal disease (ESRD) requiring dialysis can apply for a catastrophic illness card. Cardholders are exempt from the cost sharing required by the NHI program. Patients with ESRD were defined as patients who had received a catastrophic illness card for dialysis and claimed for hemodialysis or peritoneal dialysis for at least 3 months (ICD-9-CM code 585). Patients with CKD were defined as patients without ESRD who were hospitalized at least once or had 3 or more outpatient visits, in which one or more of the following ICD-9-CM diagnostic codes were used: 585–589, 250.4, 274.1, 283.11, 403.x1, 404.x2, 404.x3, 440.1, 442.1, 447.3, 572.4, 642.1x, 646.2x, and 794.4. The person-years of follow-up of the patients were estimated from the index date to the CKD diagnosis date, censoring caused by death during hospitalization, loss to follow-up, withdrawal from the insurance system, or the end of December 31, 2010. The follow-up period of CKD prognosis started from the CKD date to the end point of the study. The comorbidities included in our study were hypertension (ICD-9-CM codes 401–405), DM (ICD-9-CM code 250), hyperlipidemia (ICD-9-CM code 272), CVD (ICD-9-CM codes 410, 412, 428), cerebrovascular diseases (ICD-9-CM codes 430–438), liver disease (ICD-9-CM codes 571–572, 456.0–456.2), gout (ICD-9-CM code 274.x), obesity (ICD-9-CM code 278.x), and depression (ICD-9-CM codes 296.2, 296.3).

**Validation**

We validated the ICD-9-CM codes for the identification of NASD and CKD by analyzing the medical records (charts) of 200 patients, who had NASD ICD-9-CM code 780.52, 780.5, 780.50, 780.54, 780.55, 780.56, 780.58 and 780.59; CKD ICD-9-CM code 585 from the inpatient and outpatient claims database between January 2008 and December 2010 in Kaohsiung Municipal Ta-Tung Hospital, which is a regional teaching hospital in Taiwan. The contents of this database were similar to those of the NHIRD. The clinical diagnosis of NASD was ascertained by psychiatrists and neurologists. Clinical diagnosis of CKD was determined according to the
Estimated glomerular filtration rate < 60 mL/min/1.73 m² for more than 3 months. Positive predictive values of both diseases were estimated. There are 184 cases confirmed the diagnosis with NASD and 196 cases confirmed the diagnosis with CKD. The positive predictive value (PPV) of NASD and CKD are 0.92 and 0.98, separately.

**Statistical Analysis**

An independent *t* test, chi-square test, or Fisher’s exact test was employed for comparing the distribution of risk factors between the NASD and control cohorts. Cox proportional hazard
regression analyses were conducted to calculate the crude and adjusted hazard ratios (HRs) for the risk of CKD. Multiple Cox proportional hazard regression analyses were performed after adjustment for sex, age, and any history of hypertension, DM, hyperlipidemia, cerebrovascular disease, CVD, liver disease, gout, obesity, and depression. Kaplan–Meier curves were applied to estimate the probability of CKD onset, and the log-rank or Gehan–Breslow–Wilcoxon test was used to examine the differences among groups. Statistical analyses were performed using SAS 9.3 software (SAS Institute, Inc., Cary, NC, USA). Statistical significance was set at p < 0.05.

Results
Baseline characteristics of the study cohorts
For the period 2000–2010, we identified and selected 7,006 and 21,018 patients as the NASD and the control cohorts, respectively. The mean age of the patients was 53.91 ± 16.45 years, and 56.2% of patients in the NASD cohort were women (Table 1). The distributions of age, sex, index year, urbanization, resident region, and monthly income were similar between the 2 cohorts. Compared with the control cohort, patients in the NASD cohort had more medical visits in 1 year before the index date (p < 0.001) than did those in the control cohort. Furthermore, the patients in the NASD cohort were more likely to have comorbidities such as hypertension, DM, hyperlipidemia, CVD, cerebrovascular disease, liver disease, gout, obesity, and depression before the index date compared with those in the control cohort (p < 0.005).

Association of CKD with NASD according to age, sex, and comorbidities
During the follow-up period, the overall incidence of CKD was higher in the NASD cohort than in the control cohort (6.42 vs. 3.95 per 10,000 person-years, Table 2). After adjustment for the covariates of baseline characteristics and comorbidities, the risk of CKD was significant for patients with NASD (HR = 1.48; 95% CI = 1.26–1.73, p < 0.001). Men had a higher incidence of CKD in both cohorts and a 41% increase in the risk of CKD (p < 0.001). The incidence of CKD increased with age (p < 0.001). The age-specific relative risks of CKD were higher in middle- and old-aged adults than in young adults (aged 41–65 years, HR = 2.30, 95% CI = 1.76–3.01, p < 0.001; aged older than 65 years, HR = 4.08, 95% CI = 3.12–5.35, p < 0.001). The incidence of CKD increased for patients with preexisting comorbidities before the index date. The comorbidities included DM (HR = 1.70, 95% CI = 1.36–2.12, p < 0.001) and gout (HR = 1.84, 95% CI = 1.44–2.36, p < 0.001).

Cumulative incidences of CKD between NASD and control cohorts
We further evaluated the cumulative incidence of CKD, and the risk of CKD was significantly higher in the NASD cohort than in the control cohort (10-year cumulative incidence, 3.77% vs. 2.33%; 95% CI = 3.35%–4.24% vs. 2.13%–2.54%; log-rank test, p < 0.001), as shown in Fig 2. For women aged < 65 years, the 10-year cumulative incidence of CKD was 2.7% in the NASD cohort (HR = 1.81, 95% CI, 1.35–2.40) versus 1.5% in the control cohort. The 10-year cumulative incidence of CKD for men aged ≥ 65 years was 7.6% (HR = 2.27, 95% CI, 1.23–4.18, p = 0.009) and < 65 years was 3.0% (HR = 1.49, 95% CI, 1.09–2.04, p = 0.013) in the NASD cohort versus 1.8% of < 65 years in the control cohort (Table 3).

Subgroup analysis
We further examined the association between the risk of CKD and subgroups of NASD. The risks of CKD were significantly in the NASD subgroups of insomnia (HR = 1.52, 95% CI, 1.23–1.84, p < 0.001) and sleep disturbance (HR = 1.49, 95% CI, 1.19–1.87, p < 0.001), but not in
patients with other sleep disorders (HR = 1.00, 95% CI, 0.69–1.46, p = 0.985) (Table 4). The risk of CKD in different patient subgroups is shown in Fig 3a and 3b. After adjustment for variables, the risk of CKD was more prominent in patients in the following subgroups: female; male; aged ≤40 years; aged 41–65 years, aged >65 years; living in urban, suburban, and rural areas; living in Northern, Central, Southern and Eastern Taiwan; monthly income < NT $15,000 and between NT $15,000 and NT $30,000; without hypertension; with and without

Table 1. Demographic characteristics between the NASD cohort and control cohort (N = 28,024).

| Characteristic               | NASD cohort (n = 7,006) | Control cohort (n = 21,018) | p value |
|------------------------------|-------------------------|-----------------------------|---------|
| Age (Mean±SD)                | 53.91 (±16.45)          | 53.62 (±16.81)              | 0.208   |
| ≤40                          | 1688 (24.1)             | 5069 (24.1)                 |         |
| 41–65                        | 3466 (49.5)             | 10457 (49.8)                |         |
| >65                          | 1852 (26.4)             | 5492 (26.1)                 |         |
| Sex (%)                      |                         |                             |         |
| Female                       | 3936 (56.2)             | 11808 (56.2)                | 1.000   |
| Male                         | 3070 (43.8)             | 9210 (43.8)                 |         |
| Index Year                   |                         |                             |         |
| 2000–2003                    | 3058 (43.7)             | 9171 (43.6)                 | 0.999   |
| 2004–2006                    | 2280 (32.5)             | 6841 (32.6)                 |         |
| 2007–2009                    | 1668 (23.8)             | 5006 (23.8)                 |         |
| Urbanization                 |                         |                             |         |
| Urban                        | 2521 (36.0)             | 7563 (36.0)                 | 1.000   |
| Suburban                     | 2917 (41.6)             | 8750 (41.6)                 |         |
| Rural                        | 1568 (22.4)             | 4705 (22.4)                 |         |
| Region                       |                         |                             |         |
| Northern                     | 3794 (54.1)             | 11382 (54.1)                | 1.000   |
| Central                      | 1680 (24.0)             | 5036 (24.0)                 |         |
| Southern                     | 1286 (18.4)             | 3859 (18.4)                 |         |
| Eastern                      | 246 (3.5)               | 741 (3.5)                   |         |
| Monthly Income               |                         |                             |         |
| <15,000                      | 2564 (36.6)             | 7697 (36.6)                 | 0.999   |
| 15,000–29,999                | 3260 (46.5)             | 9780 (46.5)                 |         |
| ≥30,000                      | 1182 (16.9)             | 3541 (16.9)                 |         |
| Visit Ambulatory average frequency | 0.23 (±0.85)      | 0.11 (±0.44)                | <0.001  |
| Comorbidities (%)            |                         |                             |         |
| Hypertension                 | 1411 (20.1)             | 2191 (10.4)                 | <0.001  |
| DM                           | 570 (8.1)               | 1004 (4.8)                  | <0.001  |
| Hyperlipidemia               | 785 (11.2)              | 1242 (5.9)                  | <0.001  |
| Cerebral vascular disease    | 596 (8.5)               | 857 (4.1)                   | <0.001  |
| CVD                          | 277 (4.0)               | 506 (2.4)                   | <0.001  |
| Liver disease                | 1080 (15.4)             | 2124 (10.1)                 | <0.001  |
| Gout                         | 387 (5.5)               | 734 (3.5)                   | <0.001  |
| Obesity                      | 30 (0.4)                | 42 (0.2)                    | <0.001  |
| Depression                   | 909 (13.0)              | 467 (2.2)                   | <0.001  |

Abbreviation: NASD: nonapnea sleep disorders; SD: standard deviation; DM: type 2 Diabetes Mellitus; CVD: cardiovascular disease; COPD: chronic pulmonary disease.

doi:10.1371/journal.pone.0140401.t001
Table 2. Cox proportional hazards regression model for risk of CKD between the NSAD cohort and control cohort (N = 28,024).

|                      | Crude HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
|----------------------|-------------------|---------|----------------------|---------|
| **NASD**             |                   |         |                      |         |
| No                   | Ref.              |         | Ref.                 |         |
| Yes                  | 1.62 (1.39–1.88)  | <0.001  | 1.48 (1.26–1.73)     | <0.001  |
| **Gender**           |                   |         |                      |         |
| Female               | Ref.              |         | Ref.                 |         |
| Male                 | 1.45 (1.26–1.67)  | <0.001  | 1.41 (1.22–1.64)     | <0.001  |
| **Age**              |                   |         |                      |         |
| ≤40                  |                   |         |                      |         |
|                      |                   |         |                      |         |
| 41–65                | 2.46 (1.90–3.19)  | <0.001  | 2.30 (1.76–3.01)     | <0.001  |
| >65                  | 4.86 (3.75–6.31)  | <0.001  | 4.08 (3.12–5.35)     | <0.001  |
| **Urbanization**     |                   |         |                      |         |
| Rural                |                   |         |                      |         |
| Suburban             | 1.10 (0.90–1.33)  | 0.361   | 1.16 (0.92–1.47)     | 0.211   |
| Urban                | 1.12 (0.92–1.35)  | 0.264   | 1.21 (0.99–1.49)     | 0.059   |
| **Region**           |                   |         |                      |         |
| Northern             |                   |         |                      |         |
| Central              | 0.93 (0.78–1.11)  | 0.446   | 0.95 (0.79–1.16)     | 0.632   |
| Southern and eastern | 0.93 (0.77–1.12)  | 0.424   | 0.94 (0.76–1.17)     | 0.577   |
| **Monthly Income**   |                   |         |                      |         |
| <15,000              |                   |         |                      |         |
|                      |                   |         |                      |         |
| 15,000–29,999        | 0.88 (0.75–1.03)  | 0.102   | 0.96 (0.82–1.13)     | 0.640   |
| ≥30,000              | 0.82 (0.66–1.02)  | 0.075   | 0.86 (0.68–1.09)     | 0.219   |
| **Hypertension**     |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.97 (1.67–2.33)  | <0.001  | 1.19 (0.99–1.43)     | 0.056   |
| **DM**               |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 2.53 (2.05–3.11)  | <0.001  | 1.70 (1.36–2.12)     | <0.001  |
| **Hyperlipidemia**   |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.82 (1.47–2.25)  | <0.001  | 1.14 (0.91–1.44)     | 0.246   |
| **CVD**              |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.97 (1.43–2.72)  | <0.001  | 1.13 (0.81–1.57)     | 0.463   |
| **Cerebral vascular disease** |             |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.69 (1.31–2.19)  | <0.001  | 0.95 (0.72–1.24)     | 0.688   |
| **Liver disease**    |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.29 (1.01–1.66)  | 0.045   | 1.04 (0.80–1.34)     | 0.793   |
| **Gout**             |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 2.64 (2.08–3.36)  | <0.001  | 1.84 (1.44–2.36)     | <0.001  |
| **Obesity**          |                   |         |                      |         |
| No                   |                   |         |                      |         |
| Yes                  | 1.51 (0.38–6.05)  | 0.560   | 1.61 (0.40–6.45)     | 0.505   |

(Continued)
DM; without hyperlipidemia; without CVD; without liver disease; without gout; without obesity; and without depression in the NASD cohort (p < 0.05) (Fig 3a and 3b).

Sensitivity Analysis

When alternative all-comorbidity-matching was applied, the association pattern was similar to that obtained in the aforementioned main analyses. As shown in S1 and S2 Tables, the risk of CKD was significant for patients with NASD (HR = 1.39; 95% CI = 1.15–1.69, p = 0.001).

Discussion

We investigated the association between NASD and CKD. In this study, the risk of CKD was 1.48-fold higher in the NASD cohort than in the control cohort. An increased risk of CKD was observed in women younger than 65 years and in men of any age (men aged older than 65 years had the highest risk).

Few studies have investigated the association between NASD and CKD. Sleep disorder is highly prevalent in patients with CKD and ESRD [18,19]. Plantinga et al. [10] enrolled 9,110 participants (noninstitutionalized residents) in the United States and reported that sleep-related problems were more prevalent in patients with CKD. Agarwal et al. [20] compared the prevalence of sleep disturbances among patients with CKD receiving dialysis and those without CKD and reported that patients with CKD had lower sleep efficiency and higher sleep fragmentation, and sleep disruption in patients with CKD receiving dialysis was more severe than in those without CKD. However, the effect of CKD and its progression on renal function and various parameters of sleep quality revealed no significant linear pattern. Iseki et al. [21] recruited 5,651 people from the general population who received full-scale polysomnography, which was used as a diagnosis tool in Okinawa, Japan. OSA is more prevalent in patients with CKD than in patients without CKD. However, no cohort study has explored the association of NASD with the risk of CKD. In this cohort study, we used a large nationwide data set that afforded considerable statistical power and enabled long-term tracking of incident CKD events.

In our findings, patients in the NASD cohort had a higher risk of CKD than did those in the control cohort. Among patients with NASD, 47% of cases were diagnosed as unspecified insomnia, 35.2% were diagnosed as sleep disturbances, and 17.8% were diagnosed as other sleep disorders. In the NASD cohort, women (56.2%), patients older than 65 years (26.4%), and patients with lower monthly income (< NT$3,000, 83.1%) were predominant. The epidemiological results of this study were consistent with those of a previous population-based study in another country [22]. The prevalence of comorbidities was significantly higher in the NASD cohort than in the control cohort, and the risk of CKD was significantly high after adjustment.

Table 2. (Continued)

|                   | Crude          | Adjusted         |
|-------------------|----------------|------------------|
|                   | HR (95% CI)    | p value          | HR (95% CI)    | p value          |
| Depression        |                |                  |                |                  |
| No                | Ref.           |                  | Ref.           |                  |
| Yes               | 1.09 (0.78–1.49) | 0.595           | 0.95 (0.69–1.30) | 0.734           |

Adjusted age, gender, index year, urbanization, regions, monthly Income, visit ambulatory frequency, and comorbidities (hypertension, diabetes, hyperlipidemia, cardiovascular disease, cerebral vascular disease, liver disease, gout, obesity, depression).

doi:10.1371/journal.pone.0140401.t002

DM; without hyperlipidemia; without CVD; without liver disease; without gout; without obesity; and without depression in the NASD cohort (p < 0.05) (Fig 3a and 3b).
for all baseline covariates. Older people were at a higher risk of sleep disorders and CKD than younger people in several studies [22–25]. However, in our subgroup analysis, younger women in the NASD cohort had a higher cumulative incidence of CKD compared with those in other subgroups in the control cohort (p<0.001). Additional studies evaluating the risk of kidney disease in younger female patients may be required.
Sleep and the circadian rhythm are fundamentally biological behaviors in animals and humans who are affected by pathology, stress, and personal habits, ultimately leading to unhealthy outcomes. Healthy sleep means optimal sleep quality and quantity. Sufficient sleep can improve general conditions, such as mood, alertness, and daily performance, and has beneficial long-term health outcomes. However, impaired sleep quality and quantity may be associated with increases in blood pressure (BP), the heart rate, inflammatory markers, and glucose intolerance [26–28]. In the ancillary of Coronary Artery Risk Development in Young Adults (CARDIA) study, which enrolled 578 adults aged 33–45 years in the United States, reduced sleep duration and consolidation predicted higher BP levels and adverse changes in BP [29]. Short sleep duration was a significant risk factor for hypertension in a study on the first National Health and Nutrition Examination Survey (NHANES I), which enrolled 4,810 patients with self-reported short sleep duration [30]. In the National Institutes of Health–AARP Diet and Health Study, which enrolled 174,542 participants in the United States, short night sleeps were associated with diabetes [31]. In a meta analysis on DM comprising 10 studies, the quantity and quality of sleep predict the risk of type 2 diabetes [32]. In a cross-sectional study that enrolled 1,688 people from 2 interlinked primary care databases in the United Kingdom, patients with gout were associated with any sleep problem (odds ratio [OR]: 1.39; 95% CI: 1.06–1.81) and, specifically, sleep problems other than sleep apnea (OR: 1.37; 95% CI: 1.03–1.82) [33]. The results of these studies may explain the possible pathological mechanisms of CKD among patients with NASD.

| Table 3. The risk of CKD development between the NASD cohort and control cohort stratified by sex and age (N = 28,024). |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | <65 years old (N = 20,184) |                | ≥65 years old (N = 7840) |                |
|                | No. Cases (%) | Adjusted HR (95% CI) | p value | No. Cases (%) | Adjusted HR (95% CI) | p value |
| Female (N = 15,744) |                |                |                |                |                |
| Control cohort  | 129 (1.5) | Ref. |                | 105 (3.4) | 1.29 (0.60–2.80) | 0.519 |
| NASD cohort     | 79 (2.7) | 1.81 (1.35–2.40) | <0.001 | 50 (4.7) | 1.69 (0.76–3.77) | 0.200 |
| Male (N = 12,280) |                |                |                |                |                |
| Control cohort  | 118 (1.8) | Ref. |                | 138 (5.0) | 1.74 (0.97–3.14) | 0.064 |
| NASD cohort     | 65 (3.0) | 1.49 (1.09–2.04) | 0.013 | 70 (7.6) | 2.27 (1.23–4.18) | 0.009 |

Adjusted age, gender, index year, urbanization, regions, monthly income, visit ambulatory frequency, and comorbidities (hypertension, diabetes, hyperlipidemia, cardiovascular disease, cerebral vascular disease, liver disease, gout, depression).

doi:10.1371/journal.pone.0140401.t003

Table 4. Compared the risk of chronic kidney disease among different type NASD cohort. (N = 28,024).

| NASD cohort vs. Compared cohort | Case per 1,000 person-years | Crude HR (95% CI) | Adjusted HR (95% CI) | p value |
|---------------------------------|-----------------------------|-------------------|----------------------|---------|
| Control cohort                  | 490                         | 3.95              | Ref.                 | Ref.    |
| NASD cohort                     |                             |                   |                      |         |
| Insomnia                        | 138                         | 7.13              | 1.80 (1.49–2.17)     | 1.52 (1.23–1.84) | <0.001 |
| Sleep disturbance               | 97                          | 6.53              | 1.65 (1.33–2.05)     | 1.49 (1.19–1.87) | <0.001 |
| Other sleep disorder            | 29                          | 4.17              | 1.04 (0.72–1.51)     | 1.00 (0.69–1.46) | 0.985  |

Adjusted age, gender, index year, urbanization, regions, monthly income, visit ambulatory frequency, and comorbidities (hypertension, diabetes, hyperlipidemia, cardiovascular disease, cerebral vascular disease, liver disease, gout, depression).

doi:10.1371/journal.pone.0140401.t004
During sleep, reduced sympathetic tone and increased vagal tone cause the nocturnal decrease of BP. When people are in a sleep-debt condition, the sympathetic nervous system is activated [28]. Patients with CKD or ESRD exhibit dysregulation of the autonomic nervous system, manifesting as a failure to increase the heart rate variability [34] and leading to a dip in BP [35]. The activated sympathetic nervous system may contribute to the pathogenesis of renal hypertension and is postulated as a risk factor for CKD [36]. Circadian rhythms are linked to human homeostasis and BP. The oscillation of the renin–angiotensin–aldosterone system is

---

During sleep, reduced sympathetic tone and increased vagal tone cause the nocturnal decrease of BP. When people are in a sleep-debt condition, the sympathetic nervous system is activated [28]. Patients with CKD or ESRD exhibit dysregulation of the autonomic nervous system, manifesting as a failure to increase the heart rate variability [34] and leading to a dip in BP [35]. The activated sympathetic nervous system may contribute to the pathogenesis of renal hypertension and is postulated as a risk factor for CKD [36]. Circadian rhythms are linked to human homeostasis and BP. The oscillation of the renin–angiotensin–aldosterone system is
modulated by the circadian rhythm and rapid eye movement (REM)–non-REM cycle [37,38]. Total sleep deprivation in patients with depression leads to an increase in renin secretion and a concomitant trend for a decrease in the hypothalamic–pituitary–adrenal axis activity next night [39]. An alteration in the activity of the renin–angiotensin–aldosterone system could be another pathological mechanism of the risk of kidney disease. Sleep curtailment increased the level of proinflammatory cytokines, high sensitivity c-reactive protein and white blood cells [27,40]. In Sauvet et al. [41], vascular dysfunction was observed before an increase in sympathetic activity and systolic blood pressure with sleep deprivation. In Ohkuma et al. [42], the urinary albumin-creatinine ratio, which is a biomarker of kidney function, was associated with sleep duration in patients with type 2 diabetes. Inflammation causes glomerular endothelial dysfunction, which may lead to renal function decrease.

Huang et al. evaluated the incidence of NASD and CKD from the NHIRD and reported a significantly increased risk of CKD in patients with NASD [43]. The differences between their study and ours are the definitions of NASD and CKD, presence of comorbidities, subgroup analysis, and prognosis evaluation. The major strength of our study is that it was designed to reduce selection bias with the random sampling of a large nationwide population-based and highly representative sample, to limit detection bias of considering the use of medical services, and to mitigate environmental effects according to availability of socioeconomic indicators for all participants. Our findings of an increased risk of CKD in patients with NASD are robust because the study population was well defined and the follow-up was complete.

Limitations

Our study had several limitations. First, the lack of data on objective sleep measurement or other mental health conditions that are highly comorbid with NASD is a critical limitation. Second, diseases may be inaccurately classified when an administrative database is used. To counter this concern, NASD was diagnosed according to both ICD-9-CM codes and benzodiazepine use. Moreover, the NHIRD lacks information on body weight, laboratory data, lifestyle, and family history of kidney disease; all of which may contribute to the risk of CKD. Therefore, these variables could not be included in the propensity analysis because adjustment could not be performed, leading to the difference in propensity scores between the cohorts. Therefore, we added the CCI score to the propensity score in multivariate and stratified analyses to control for confounding by these variables. Finally, NHIRD is a disconnected research database. The unknown of symptom period of NASD may cause an underestimation of the incidence of CKD in patients with NASD. Despite these limitations, this study had several strengths. This was a longitudinal nationwide population-based cohort study on an Asian population regarding the association between NASD and the risk of subsequent CKD events. Our findings may benefit further analysis in future studies regarding specific sleep disorders contributing to CKD incidence.

Conclusion

In this Taiwanese nationwide population-based cohort study, NASD was significantly associated with increased risks of CKD, particularly in men and women younger than 65 years.
Enhancing sleep disorder management may be vital for CKD prevention because of the increase in the number of patients with NASD.

Supporting Information
S1 Table. Demographic characteristics between the NASD cohort and control cohort matched with sex, age, index year and comorbidities with 1:1 ratio.
(DOCX)

S2 Table. Comparison of the risk of CKD between the NASD cohort and control cohort.
(DOCX)

Acknowledgments
The authors appreciate the assistance from the Statistical Analysis Laboratory, Kaohsiung Municipal Ta-Tung Hospital.

Author Contributions
Conceived and designed the experiments: HYL SH. Performed the experiments: CH YC ML. Analyzed the data: MY SL WL. Contributed reagents/materials/analysis tools: HC. Wrote the paper: HYL SH.

References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72(3):247–59. doi:10.1038/sj.ki.5002343 PMID: 17586785.

2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038–47. doi:10.1001/jama.298.17.2038 PMID: 17986697.

3. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008; 371(9631):2173–82. doi:10.1016/S0140-6736(08)60952-6 PMID: 18596172.

4. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney Int. 2012; 81(4):551–62. doi:10.1038/ki.2011.380 PMID: 22166846.

5. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013; 61(1):134–46. doi:10.1053/j.ajkd.2012.07.021 PMID: 23058478; PubMed Central PMCID: PMC3525781.

6. Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD—what should nephrologists know? J Am Soc Nephrol. 2013; 24(11):1727–36. doi:10.1681/ASN.2013040330 PMID: 24115475; PubMed Central PMCID: PMC3680991.

7. Massy ZA, de Zeeuw D. LDL cholesterol in CKD—to treat or not to treat? Kidney Int. 2013; 84(3):451–6. doi:10.1038/ki.2013.181 PMID: 23698234.

8. Shankar A, Sun L, Klein BE, Lee KE, Muntnar P, Nieto FJ, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011; 80(11):1231–8. doi:10.1038/ki.2011.283 PMID: 21866069; PubMed Central PMCID: PMC3260339.

9. Buysse DJ. Insomnia. JAMA. 2013; 309(7):706–16. doi:10.1001/jama.2013.193 PMID: 23423416; PubMed Central PMCID: PMC3632369.

10. Plantinga L, Lee K, Inker LA, Saran R, Yee J, Gillespie B, et al. Association of sleep-related problems with CKD in the United States, 2005–2008. Am J Kidney Dis. 2011; 58(4):554–64. doi:10.1053/j.ajkd.2011.05.024 PMID: 21816524.

11. Sakaguchi Y, Shoji T, Kawabata H, Nihata K, Suzuki A, Kaneko T, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol. 2011; 6(5):995–1000. doi:10.2215/CJN.08870910 PMID: 21415314; PubMed Central PMCID: PMC3087795.
12. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. The New England journal of medicine. 2000; 342(19):1378–84. doi: 10.1056/NEJM2000051131421901 PMID: 10805822.

13. Narkiewicz K, Montano N, Cogliati C, van de Borne PJ, Dyken ME, SomersVK. Altered cardiovascular variability in obstructive sleep apnea. Circulation. 1998; 98(11):1071–7. PMID: 9736593.

14. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002; 105(21):2462–4. PMID: 12034649.

15. Prabhakar NR. Sleep apneas: an oxidative stress? Am J Respir Crit Care Med. 2002; 165(7):859–60. doi: 10.1164/ajrccm.165.7.2202030c PMID: 11934709.

16. TM C, Taiwan’s National Health Insurance system: high value for the dollar. In: Okma KG, Crivelli L, editors Six countries, six reform models: the health reform experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan.71

17. Chung WS, Lin CL, Chen YF, Chiang JY, Sung FC, Chang YJ, et al. Sleep disorders and increased risk of subsequent acute coronary syndrome in individuals without sleep apnea: a nationwide population-based cohort study. Sleep. 2013; 36(12):1963–8. doi: 10.5656/sleep.3240 PMID: 24293772; PubMed Central PMCID: PMC3825447.

18. Bent RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis. 2000; 35(6):1052–60. PMID: 10845816.

19. Hanly P. Sleep apnea and daytime sleepiness in end-stage renal disease. Semin Dial. 2004; 17(2):109–14. doi: 10.1111/j.0894-0959.2004.17206.x PMID: 15043611.

20. Agarwal R, Light RP. Sleep and activity in chronic kidney disease: a longitudinal study. Clin J Am Soc Nephrol. 2011; 6(6):1258–65. doi: 10.2215/CJN.10581110 PMID: 21415310; PubMed Central PMCID: PMC3109920.

21. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertension research: official journal of the Japanese Society of Hypertension. 2008; 31(2):249–55. doi: 10.1291/hypres.31.249 PMID: 18360044.

22. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep. 2007; 30(3):274–80. PMID: 17425223.

23. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep. 1991; 14(5):392–8. PMID: 1759091.

24. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest. 1987; 91(4):540–6. PMID: 3829746.

25. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2003; 14(7 Suppl 2):S131–8. PMID: 12819318.

26. Tchikubo O, Ikeda A, Miyajima E, Ishii M. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension. 1996; 27(6):1318–24. PMID: 8641742.

27. Meier-Ewert HK, Rickard PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004; 43(4):678–83. doi: 10.1016/j.jacc.2003.07.050 PMID: 14975482.

28. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999; 354(9188):1435–9. doi: 10.1016/S0140-6736(99)01376-8 PMID: 10543671.

29. Knutson KL, Van Cauter E, Rathouz PJ, Yan LL, Hulley SB, Liu K, et al. Association between sleep and blood pressure in midlife: the CARDIA sleep study. Archives of internal medicine. 2009; 169(11):1055–61. doi: 10.1001/archintermed.2009.119 PMID: 19506175; PubMed Central PMCID: PMC3825447.

30. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buys RM, Kreier F, Pickering TG, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension. 2006; 47(5):833–9. doi: 10.1161/HYPERTENSIONAHA.105.063478 PMID: 16585410.

31. Xu Q, Song Y, Hollenbeck A, Blair A, Schatzkin A, Chen H. Day napping and short night sleeping are associated with higher risk of diabetes in older adults. Diabetes care. 2010; 33(1):78–83. doi: 10.2337/dc09-1143 PMID: 19825823; PubMed Central PMCID: PMC2797990.

32. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes care. 2010; 33(2):414–20. doi: 10.2337/dc09-1124 PMID: 19910503; PubMed Central PMCID: PMC2809295.

33. Roddy E, Muller S, Hayward R, Mallen CD. The association of gout with sleep disorders: a cross-sectional study in primary care. BMC musculoskeletal disorders. 2013; 14:119. doi: 10.1186/1471-2474-14-119 PMID: 23957073; PubMed Central PMCID: PMC3621781.
34. Roumelioti ME, Ranpuria R, Hall M, Hotchkiss JR, Chan CT, Unruh ML, et al. Abnormal nocturnal heart rate variability response among chronic kidney disease and dialysis patients during wakefulness and sleep. Nephrol Dial Transplant. 2010; 25(11):3733–41. doi: 10.1093/ndt/gfq234 PMID: 20466675; PubMed Central PMCID: PMC2980993.

35. Agarwal R, Light RP. GFR, proteinuria and circadian blood pressure. Nephrol Dial Transplant. 2009; 24(8):2400–6. doi: 10.1093/ndt/gfp074 PMID: 19251741.

36. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004; 65(5):1568–76. doi: 10.1111/j.1523-1755.2004.00552.x PMID: 15086894.

37. Brandenberger G, Follenius M, Goichot B, Saini J, Spiegel K, Ehrhart J, et al. Twenty-four-hour profiles of plasma renin activity in relation to the sleep-wake cycle. Journal of hypertension. 1994; 12(3):277–83. PMID: 8021481.

38. Charloux A, Gronfier C, Lonsdorfer-Wolf E, Piquard F, Brandenberger G. Aldosterone release during the sleep-wake cycle in humans. The American journal of physiology. 1999; 276(1 Pt 1):E43–9. PMID: 9886949.

39. Murck H, Uhr M, Ziegenbein M, Kunzel H, Held K, Antonijevic IA, et al. Renin-angiotensin-aldosterone system, HPA-axis and sleep-EEG changes in unmedicated patients with depression after total sleep deprivation. Pharmacopsychiatry. 2006; 39(1):23–9. doi: 10.1055/s-2006-931476 PMID: 16453251.

40. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab. 2004; 89(5):2119–26. doi: 10.1210/jc.2003-031562 PMID: 15126529.

41. Sauvet F, Leftheriotis G, Gomez-Merino D, Langrume C, Drogou C, Van Beers P, et al. Effect of acute sleep deprivation on vascular function in healthy subjects. Journal of applied physiology. 2010; 108(1):68–75. doi: 10.1152/japplphysiol.00851.2009 PMID: 19910332.

42. Ohkuma T, Fuji H, Iwase M, Ogata-Kaizu S, Ide H, Kikuchi Y, et al. Association between sleep duration and urinary albumin excretion in patients with type 2 diabetes: the Fukuoka diabetes registry. PLOS ONE, 2013; 8(11):e78968. doi: 10.1371/journal.pone.0078968 PMID: 24265736; PubMed Central PMCID: PMC3827127.

43. Huang ST, Lin CL, Yu TM, Yang TC, Kao CH. Nonapnea sleep disorders and incident chronic kidney disease: a population-based retrospective cohort study. Medicine. 2015; 94(4):e429. doi: 10.1097/MD.0000000000000429 PMID: 25634175.